Validation of a Single Item Measure for Financial Toxicity Screening in Patients With Breast Cancer
- 24 January 2025
- journal article
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- p. OP2400753
Abstract
PURPOSE: Financial toxicity (FT) has been linked to higher symptom burden and poorer clinical outcomes for patients with cancer. Despite the availability of validated tools to measure FT, a simple screen remains an unmet need. We evaluated item 12 (“My illness has been a financial hardship to my family and me”) of the COmprehensive Score for Financial Toxicity (COST) measure as a single-item FT screening measure. METHODS: In this secondary analysis, 711 patients with cancer (690 with breast cancer) were recruited via a web-based survey from a philanthropic organization. COST items 1-11 were scored according to Functional Assessment of Chronic Illness Therapy scoring guidelines, with lower scores indicating worse FT. Analyses focused on establishing a correlation, examining item properties, and sensitivity/specificity of item 12 relative to the total COST score. RESULTS: Item 12 had a correlation of r = 0.53 with the COST-11 score, and an increase of one point on item 12 is associated with a decrease of approximately three total points on the full scale ( b , 3.35; P < .001; adjusted R 2 , 0.28). Item analysis with the graded-response item in response theory modeling showed very good discrimination ( a , 2.096) for item 12, indicating that it can reliably distinguish between low and high FT in patients. Sensitivity ranged between 75.6% and 95.7% on all item 12 thresholds to screen positive for FT using two COST cutoffs as criteria. Maximizing both sensitivity and specificity was to be found for higher item 12 scores. CONCLUSION: To our knowledge, this is the first validation of a single-item screening measure for FT. Overall, these results illustrate that item 12 from the COST measure is a good candidate for a single-item screener. Clinicians can choose among item 12 screening thresholds depending on their tolerance for low specificity.Keywords
This publication has 53 references indexed in Scilit:
- Development and validation of FinTox: A new screening tool to assess cancer‐related financial toxicityCancer Medicine, 2024
- Interventions to mitigate cancer‐related medical financial hardship: A systematic review and meta‐analysisCancer, 2024
- Monitoring Adverse Effects of Radiation Therapy in Patients With Head and Neck CancerJAMA Otolaryngology–Head & Neck Surgery, 2023
- The cost of cure: Examining objective and subjective financial toxicity in head and neck cancer survivorsHead & Neck, 2021
- Unmet need for clinician engagement regarding financial toxicity after diagnosis of breast cancerCancer, 2018
- Measuring financial toxicity as a clinically relevant patient‐reported outcome: The validation of the COmprehensive Score for financial Toxicity (COST)Cancer, 2016
- Feasibility of a psychosocial and patient navigation intervention to improve access to treatment among underserved breast cancer patientsSupportive Care in Cancer, 2014
- Economic stress among low‐income women with cancerCancer, 2007
- Patient-Physician Communication About Out-of-Pocket CostsJAMA, 2003
- Estimation of Latent Ability Using a Response Pattern of Graded ScoresPsychometrika, 1969